FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985706057> ?p ?o ?g. }

• W1985706057 endingPage "975" @default.
• W1985706057 startingPage "973" @default.
• W1985706057 abstract "Several years ago for this same journal, I wrote an editorial entitled “Asthma and Gastroesophageal Reflux Disease: The Truth Is Difficult To Define.”1Richter JE Asthma and gastroesophageal reflux disease: the truth is difficult to define.Chest. 1999; 116: 1150-1152Abstract Full Text Full Text PDF Scopus (16) Google Scholar In that editorial and another review article,2Kavuru MS Richter JE Medical treatment of gastroesophageal reflux disease and airway disease.in: Stein MR Gastroesophageal reflux disease and airway disease. Marcel Dekker, New York, NY1999: 179-207Crossref Google Scholar I outlined the major limitations in current studies on this subject and lamented our progress over the last 20 years in resolving this complex interaction. Over the last 3 years in the adult literature, it is disappointing that only one study has addressed this subject using a placebo-controlled crossover design and omeprazole, 40 mg for 4 weeks.3Harmanci E Entok E Metintar M et al.Gastroesophageal reflux in patients with asthma.Allergol Immunopathol (Madr). 2001; 29: 123-128Crossref PubMed Scopus (14) Google Scholar The sample size was only five patients, and they found no improvement in pulmonary function tests results. On the other hand, this issue of CHEST (see page 1008) has an excellent study by Khoshoo and colleagues, which overcomes many of the methodological limitations of other studies and defines better the role of gastroesophageal reflux disease (GERD) treatment with proton pump inhibitors (PPIs) in children with difficult-to-control asthma. Impressively, this study was not performed in an academic medical center but rather by dedicated physicians in private practice who are interested in asthma and GERD, and who worked together to define an effective clinical algorithm for approaching all of their difficult-to-manage asthma patients. Let us look at the relevance of this important study to the methodological limitations of many previous studies relating asthma and GERD.2Kavuru MS Richter JE Medical treatment of gastroesophageal reflux disease and airway disease.in: Stein MR Gastroesophageal reflux disease and airway disease. Marcel Dekker, New York, NY1999: 179-207Crossref Google Scholar These authors do a commendable job in defining their asthma population and the failure of those patients to respond to optimal asthma therapy. Children with the following criteria were included in the study: (1) no family history of asthma; (2) no personal or family history of atopic disease; (3) parents who did not smoke; and (4) no history of respiratory syncytial virus bronchitis. All children had been treated for their asthma for > 2 years, and their conditions were difficult to manage, with at least three emergency department visits or hospital admissions in the last year, despite aggressive management of their asthma with a combination of short-acting and long-acting bronchodilators, leukotriene antagonists, and inhaled/oral corticosteroids. Despite this difficult group of patients, all of those individuals with abnormal 24-h pH studies (27 subjects) had at least a 50% reduction in their need for medications after 1 year of follow-up, while receiving lansoprazole, 30 mg, in the morning and a prokinetic drug. In the vast majority of patients, therapy with long-acting bronchodilators, leukotriene antagonists, and inhaled/oral steroids could be discontinued because the patient's asthma could be easily controlled with as-needed puffs of short-acting bronchodilators. Over a 2.5-year period, 482 patients with asthma of > 2 years’ duration were screened. A total of 46 consecutive patients (10%) with difficult-to-control asthma were referred to a pediatric gastroenterologist to rule out GERD and fulfilled all the entrance criteria for study enrollment. None of the patients were lost to follow-up, and all were treated by a team of experienced pediatric gastroenterologists and asthma specialists. Symptoms were assessed by personal diaries and the use of asthma drugs, the doses of which were adjusted based on National Institutes of Health guidelines4National Asthma Education and Prevention Program Expert panel report 2: guidelines for the diagnosis and management of asthma. National Institutes of Health, Bethesda MDApril 1997Google Scholar and symptom responses that were observed for > 1 year. The number of patients studied was very respectable, exceeding the number in all but two previous studies reported in the medical/surgical literature on this subject.5Harding SM Sontag SJ Asthma and gastroesophageal reflux.Am J Gastroenterol. 2000; 95: S23-S32Crossref PubMed Google Scholar Furthermore, these authors give us a realistic idea of the percentage of children who clinically require this approach, which is much more relevant than the reported GERD prevalence rates of 33 to 90% of asthmatic patients from various study populations.5Harding SM Sontag SJ Asthma and gastroesophageal reflux.Am J Gastroenterol. 2000; 95: S23-S32Crossref PubMed Google Scholar I believe this is one of the strongest features of the study by Khoshoo et al. Rather than using subjective symptom complaints, the authors required as their criteria of success a 50% reduction in the use of various classes of asthmatic drugs compared to the patient's pretreatment baseline needs. This replicates the situation in clinical practice, in which dose adjustment is a gestalt consisting of patient symptom improvement and the improvement of various pulmonary function test results, such as peak expiratory flow rates. Using these clinically relevant criteria, 100% of the asthma patients with abnormal pH study findings who had been treated either medically (18 subjects) or surgically with fundoplication (9 subjects) had a significant reduction in their asthma medications over the 1-year study period, compared to a 20% reduction in medications among those patients with no documented GERD on pH testing who opted for a therapeutic trial of medical antireflux treatment (8 subjects) or who did not receive any antireflux treatment (11 subjects). This is a second very strong feature of this PPI study in children with asthma. The authors wisely chose a 1-year window in which to assess the success of their treatment regimen compared to the 6-month period prior to referral for reflux evaluation. In fact, the initial 6-month phase of therapy was considered a “washout period” and only the last 6 months, after either medical or surgical treatment, were used for analysis. This was similar to the techniques that Harding et al6Harding SM Richter JE Guzzo MR et al.Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcomes.Am J Gastroenterol. 1996; 100: 395-405Scopus (350) Google Scholar used in a study assessing the efficacy of omeprazole therapy with documented pH control by serial testing, although the study duration was only 3 months of reflux controlled with omeprazole therapy in doses ranging from 20 to 60 mg. Longer treatment periods are mandatory for the appropriate assessment of clinically relevant parameters of success (ie, reduction in drug usage) and take into consideration seasonal variations of asthma. In children, this study convincingly shows that the presence of abnormal amounts of distal and proximal reflux measured by 24-h pH testing was highly predictive of the successful response to lansoprazole and prokinetic drug therapy. In fact, only 20% of children with normal pH study findings got better over the 1-year follow-up period, either spontaneously or after receiving antireflux therapy. These results compliment similar findings in large adult studies by Harding et al6Harding SM Richter JE Guzzo MR et al.Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcomes.Am J Gastroenterol. 1996; 100: 395-405Scopus (350) Google Scholar and Kiljander et al.7Kiljander TO Salomaa ERM Hietanan EK et al.Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole.Chest. 1999; 116: 1257-1264Abstract Full Text Full Text PDF PubMed Scopus (200) Google Scholar Furthermore, it is this observer's belief that all future studies assessing the relationship between asthma and GERD should require baseline pH testing and segregation of populations based on these results. In clinical practice, this may not be realistic, but certainly all difficult-to-manage asthmatic patients should undergo 24-h pH testing, as has been suggested by Irwin et al.8Irwin RS Curley FJ French CC Difficult-to-control asthma: contributing factors and outcomes of a systematic management protocol.Chest. 1993; 115: 654-659Google Scholar Interestingly, this study also supports other predictors of success reported in the literature, including the presence of nonallergic asthma and difficult-to-control asthma.5Harding SM Sontag SJ Asthma and gastroesophageal reflux.Am J Gastroenterol. 2000; 95: S23-S32Crossref PubMed Google Scholar No study is perfect, and neither was this one. For ethical reasons, a placebo control was not used. However, this seems a minor shortcoming considering that data from a variety of experimental trials of anti-inflammatory agents for treatment of chronic steroid-dependent asthma find only a 20 to 40% improvement from simply participating in a clinical trial.2Kavuru MS Richter JE Medical treatment of gastroesophageal reflux disease and airway disease.in: Stein MR Gastroesophageal reflux disease and airway disease. Marcel Dekker, New York, NY1999: 179-207Crossref Google Scholar Furthermore, their group with a normal pH test finding really serves as an adequate control with a spontaneous rate of improvement of only 20%. The authors criticized themselves for not using a crossover design, but I believe this study technique is inappropriate in these trials when a placebo is used because order and carryover effects regularly bias the data, making them more difficult to logically analyze. Rather, placebo control studies for asthma and GERD should employ a parallel design with separate groups of treated and control patients. As with all medical studies except one,6Harding SM Richter JE Guzzo MR et al.Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcomes.Am J Gastroenterol. 1996; 100: 395-405Scopus (350) Google Scholar the control of GERD with lansoprazole was not assessed by serial pH testing. However, this is unrealistic in the clinical setting and is very difficult to accomplish in large patient trials. Furthermore, who is to argue with the adequacy of PPI therapy when 100% of treated patients responded well? It is only a factor in the treated patients who did not respond, but this was unlikely to be much of a factor as these patients had normal baseline pH tests. Finally, we do not know if these data only apply to patients with symptomatic GERD or is also useful for the many asthmatics with “silent” GERD. Symptom data about GERD were not given in the patient summaries and the criteria for referral to a gastroenterologist appears to only be the difficult-to-manage quality of their asthma. Addressing this issue in future studies is important as 40 to 60% of asthmatic patients have silent reflux, while a recent study9Harding SM Guzzo MR Richter JE The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms.Am J Respir Crit Med. 2000; 162: 34-39Crossref PubMed Scopus (212) Google Scholar found their 24-h pH profiles similar to those of asthmatic patients with symptomatic GERD. Khoshoo and colleagues are to be congratulated for performing a practical clinical study that is the first of its kind in the pediatric population to assess the role of PPIs in treating patients with GERD associated with asthma. Although it is not the perfect study, many of its features helped to overcome previous methodological problems that occurred in other asthma and GERD studies. Hopefully, other centers, both academic and private practice, will continue to address this issue, and maybe in time we will have the perfect placebo-controlled parallel study with long follow-up and pertinent clinical outcome parameters to satisfy our colleagues in evidence-based medicine. Until that time, we are wiser and can help our patients more based on sound clinical observational studies with carefully outlined clinical treatment algorithms, such as that reported in this issue of CHEST." @default.
• W1985706057 created "2016-06-24" @default.
• W1985706057 creator A5011290043 @default.
• W1985706057 date "2003-04-01" @default.
• W1985706057 modified "2023-09-25" @default.
• W1985706057 title "Not the Perfect Study, but Helpful Wisdom for Treating Asthma Patients With Gastroesophageal Reflux Disease" @default.
• W1985706057 cites W1972275318 @default.
• W1985706057 cites W2013001000 @default.
• W1985706057 cites W2035035599 @default.
• W1985706057 cites W2040391660 @default.
• W1985706057 cites W2055101760 @default.
• W1985706057 cites W2062071217 @default.
• W1985706057 cites W2092864745 @default.
• W1985706057 cites W2112551683 @default.
• W1985706057 cites W2468851542 @default.
• W1985706057 cites W2585717783 @default.
• W1985706057 cites W603138678 @default.
• W1985706057 doi "https://doi.org/10.1378/chest.123.4.973" @default.
• W1985706057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12684276" @default.
• W1985706057 hasPublicationYear "2003" @default.
• W1985706057 type Work @default.
• W1985706057 sameAs 1985706057 @default.
• W1985706057 citedByCount "2" @default.
• W1985706057 crossrefType "journal-article" @default.
• W1985706057 hasAuthorship W1985706057A5011290043 @default.
• W1985706057 hasBestOaLocation W19857060571 @default.
• W1985706057 hasConcept C126322002 @default.
• W1985706057 hasConcept C177713679 @default.
• W1985706057 hasConcept C2776042228 @default.
• W1985706057 hasConcept C2777014526 @default.
• W1985706057 hasConcept C2779134260 @default.
• W1985706057 hasConcept C43270747 @default.
• W1985706057 hasConcept C71924100 @default.
• W1985706057 hasConcept C90924648 @default.
• W1985706057 hasConceptScore W1985706057C126322002 @default.
• W1985706057 hasConceptScore W1985706057C177713679 @default.
• W1985706057 hasConceptScore W1985706057C2776042228 @default.
• W1985706057 hasConceptScore W1985706057C2777014526 @default.
• W1985706057 hasConceptScore W1985706057C2779134260 @default.
• W1985706057 hasConceptScore W1985706057C43270747 @default.
• W1985706057 hasConceptScore W1985706057C71924100 @default.
• W1985706057 hasConceptScore W1985706057C90924648 @default.
• W1985706057 hasIssue "4" @default.
• W1985706057 hasLocation W19857060571 @default.
• W1985706057 hasLocation W19857060572 @default.
• W1985706057 hasOpenAccess W1985706057 @default.
• W1985706057 hasPrimaryLocation W19857060571 @default.
• W1985706057 hasRelatedWork W189068475 @default.
• W1985706057 hasRelatedWork W2005062188 @default.
• W1985706057 hasRelatedWork W2017418829 @default.
• W1985706057 hasRelatedWork W2022311620 @default.
• W1985706057 hasRelatedWork W2041638752 @default.
• W1985706057 hasRelatedWork W2356299640 @default.
• W1985706057 hasRelatedWork W2381168924 @default.
• W1985706057 hasRelatedWork W2992861500 @default.
• W1985706057 hasRelatedWork W3118258997 @default.
• W1985706057 hasRelatedWork W3141685975 @default.
• W1985706057 hasVolume "123" @default.
• W1985706057 isParatext "false" @default.
• W1985706057 isRetracted "false" @default.
• W1985706057 magId "1985706057" @default.
• W1985706057 workType "article" @default.